Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Intellia Therapeutics Inc (38I)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
19.2550 -0.0750    -0.39%
26/04 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 55
  • Bid/Ask: 19.3350 / 19.4450
  • Day's Range: 18.4600 - 19.2550
Type:  Equity
Market:  Germany
ISIN:  US45826J1051 
S/N:  A2AG6H
Intellia Therapeutics Inc 19.2550 -0.0750 -0.39%

Intellia Therapeutics Inc Company Profile

 
Read the Intellia Therapeutics Inc company profile to learn more about the business and the management team. View Intellia Therapeutics Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

526

Equity Type

ORD

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 40 Erie Street Suite 130
Cambridge, 02139
United States
Phone 857 285 6200
Fax -

Top Executives

Name Age Since Title
Franciscus A. G. M. Verwiel 59 2017 Independent Chairman of the Board
John M. Leonard 64 2014 President, CEO & Director
Andrew May - - Founder and Member of Scientific Advisor Board
Nessan Bermingham 50 2014 Founder & Member of Scientific Advisor Board
Rodolphe Barrangou - - Founder & Member of Scientific Advisor Board
Derrick J. Rossi - 2015 Founder & Member of Scientific Advisor Board
Erik J. Sontheimer - - Founder & Member of Scientific Advisor Board
Luciano Marraffini - - Founder & Member of Scientific Advisor Board
Arthur M. Krieg 66 - Member of Scientific Advisory Board
Jesse L. Goodman 71 2018 Independent Director
Georgia Keresty 61 2021 Independent Director
Muna Bhanji 60 2022 Independent Director
Beverly L. Davidson - 2015 Member of Scientific Advisory Board
Fred E. Cohen 67 2019 Independent Director
William J. Chase 55 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NTLA Price Commentary

Write your thoughts about Intellia Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Joakim Gasslander
Joakim Gasslander Aug 10, 2021 9:21
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wake me up when its printing 20.
KazBreh JR
KazBreh JR Jul 02, 2021 2:01
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target for tomorrow?
Joakim Gasslander
Joakim Gasslander Jun 08, 2020 15:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wake me up when its printing 200.
Horun Meaj
Horun Meaj Jun 08, 2020 15:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wake up
Max Ps
Max Ps Jun 08, 2020 15:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
alright buddy time to wake up
Russ Mafi
Russ Mafi Jun 08, 2020 15:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
its time pal....200
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email